VWD affects up to 1% of the global population, and is caused by deficiency or dysfunction in the protein known as von Willebrand factor (VWF). Veyvondi is used to treat haemorrhage and surgical ...

Antiphospholipid antibodies (present in the serum of patients with APS) are known to induce platelet activation and the production of procoagulants such as von Willebrand factor, thereby ...